Position in JANX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$49,345,000
+$16,328,183 QoQ
Shares Held
3,550,000
+48.4% QoQ
Ownership
5.82%
of shares outstanding
% of Portfolio
8.09%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Prosight Management, LP holds $368,598,367 across 29 Biotechnology names. JANX ranks #2 (13.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NKTR |
Nektar Therapeutics
|
735,000 | $52,883,250 | |
| 2 | JANX |
Janux Therapeutics, Inc.
This page
|
3,550,000 | $49,345,000 | |
| 3 | LKFT |
Lakefront Biotherapeutics NV
|
1,550,000 | $46,500,000 | |
| 4 | STTK |
Shattuck Labs, Inc.
|
5,004,439 | $32,178,542 | |
| 5 | KURA |
Kura Oncology, Inc.
|
3,356,700 | $27,289,971 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
76,000 | $25,146,120 | |
| 7 | MGTX |
MeiraGTx Holdings plc
|
2,629,971 | $22,775,548 | |
| 8 | SNDX |
Syndax Pharmaceuticals Inc
|
770,000 | $17,987,200 |
All Filings in JANX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $49,345,000 | 3,550,000 | Shares | Sole | 2026-05-15 | |
| 2026-02-03 | $43,569,636 | 3,157,220 | Shares | Sole | 2026-02-06 | |
| 2025-12-31 | $33,016,817 | 2,392,523 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $21,149,154 | 865,350 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $19,725,182 | 853,904 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $18,627,327 | 689,901 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $17,655,778 | 329,768 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $9,313,150 | 205,000 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||